-
公开(公告)号：US20170029492A1
公开(公告)日：2017-02-02
申请号：US15293508
申请日：2016-10-14
IPC分类号： C07K16/18
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
摘要翻译： 本发明提供通过向有需要的受试者施用特异性结合人类δ样配体4（hDll4）并阻断hDll4的人抗体或其片段来治疗，改善或抑制肿瘤生长，癌症或病理性血管发生的方法 与Notch受体结合。 本发明的抗hDll4抗体或其片段通过表面等离振子共振测得的具有500pM以下的KD的高亲和力。
-
公开(公告)号：US11820815B2
公开(公告)日：2023-11-21
申请号：US16892336
申请日：2020-06-04
CPC分类号： C07K16/22 , C07K16/18 , A61K2039/505 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
-
公开(公告)号：US20150376267A1
公开(公告)日：2015-12-31
申请号：US14729218
申请日：2015-06-03
IPC分类号： C07K16/18
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
-
公开(公告)号：US20220025030A1
公开(公告)日：2022-01-27
申请号：US16892336
申请日：2020-06-04
摘要： The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
-
公开(公告)号：US20150232545A1
公开(公告)日：2015-08-20
申请号：US14176523
申请日：2014-02-10
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
摘要翻译： 本发明提供通过向有需要的受试者施用特异性结合人类δ样配体4（hDll4）并阻断hDll4的人抗体或其片段来治疗，改善或抑制肿瘤生长，癌症或病理性血管发生的方法 与Notch受体结合。 本发明的抗hDll4抗体或其片段通过表面等离振子共振测得的具有500pM以下的KD的高亲和力。
-
公开(公告)号：US20130302356A1
公开(公告)日：2013-11-14
申请号：US13948919
申请日：2013-07-23
IPC分类号： A61K39/395 , A61K45/06
CPC分类号： C07K16/18 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.
-
公开(公告)号：US20150191534A1
公开(公告)日：2015-07-09
申请号：US14524164
申请日：2014-10-27
IPC分类号： C07K16/18
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
-
8.发明申请Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent 审中-公开用DLL4拮抗剂和化学治疗剂治疗癌症的方法公开(公告)号：US20150064189A1
公开(公告)日：2015-03-05
申请号：US14457968
申请日：2014-08-12
IPC分类号： C07K16/18 , A61K33/24 , A61K31/513 , A61K31/519 , A61K31/4745 , A61K31/7068 , A61K31/282 , A61K31/337 , A61K39/395
CPC分类号： C07K16/18 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.
摘要翻译： 本发明提供了通过施用特异性结合人Dll4的Dll4拮抗剂，特别是Dll4抗体及其片段以及化学治疗剂的组合来治疗各种类型的癌症/肿瘤的方法。 与单独使用任一试剂的治疗相比，这种联合疗法表现出协同效应。 因此，通过能够降低有效剂量，本发明的方法对于通过单独的任一药物治疗所需的高剂量引起的副作用耐受性低的癌症患者特别有益。 还提供了含有Dll4拮抗剂和化学治疗剂的药物组合物和试剂盒。
-
9.发明授权公开(公告)号：US08840886B2
公开(公告)日：2014-09-23
申请号：US13948919
申请日：2013-07-23
IPC分类号： A61K39/395 , C07K14/435 , C07K14/475 , A61K45/06 , C07K16/22 , A61K39/00
CPC分类号： C07K16/18 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.
摘要翻译： 本发明提供了通过施用Dll4拮抗剂，特别是Dll4抗体及其与人Dll4特异性结合的片段的组合以及化学治疗剂来治疗各种类型的癌症/肿瘤的方法。 与单独使用任一试剂的治疗相比，这种联合疗法表现出协同效应。 因此，本发明的方法对于通过能够降低有效剂量而对由单独的任一药物治疗所需的高剂量引起的副作用的耐受性低的癌症患者特别有益。 还提供了含有Dll4拮抗剂和化学治疗剂的药物组合物和试剂盒。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.027 秒)
